Reversal of Pathogen-Induced Barrier Defects in Intestinal Epithelial Cells by Contra-pathogenicity Agents

Dig Dis Sci. 2021 Jan;66(1):88-104. doi: 10.1007/s10620-020-06121-9. Epub 2020 Feb 7.

Abstract

Background: Environmental enteropathy (EE) is associated with stunting, impairment of responses to oral vaccines, and other adverse health consequences in young children throughout the developing world. EE is characterized by chronic low-grade intestinal inflammation and disrupted epithelial barrier integrity, partly resulting from dysregulation of tight junction proteins, observed in other enteropathies such as celiac disease. During EE, this dysregulation of tight junction expression amplifies translocation of pathogenic bacteria across the intestinal mucosa.

Aims: The aim was to determine whether enteropathogen-mediated epithelial barrier failure can be ameliorated using contra-pathogenicity therapies.

Methods: Intestinal epithelial barrier damage was assessed in Caco-2 cells incubated with three important enteropathogens identified in EE patients: Enteropathogenic Escherichia coli (EPEC), Citrobacter rodentium (C. rodentium), and Cryptosporidium parvum (C. parvum). Potential therapeutic molecules were tested to detect effects on transepithelial resistance (TER), bacterial translocation (BT), claudin-4 expression, and regulation of the inflammatory cytokine response.

Results: All three enteropathogens compared to uninfected cells, reduced TER (EPEC; p < 0.0001, C. rodentium; p < 0.0001, C. parvum; p < 0.0007), reduced claudin-4 expression, and permitted BT (EPEC; p < 0.0001, C. rodentium; p < 0.0001, C. parvum; p < 0.0003) through the monolayer. Zinc, colostrum, epidermal growth factor, trefoil factor 3, resistin-like molecule-β, hydrocortisone, and the myosin light chain kinase inhibitor ML7 (Hexahydro-1-[(5-iodo-1-naphthalenyl)sulfonyl]-1H-1,4-diazepine hydrochloride); ML7) improved TER (up to 70%) and decreased BT (as much as 96%). Only zinc demonstrated modest antimicrobial activity.

Conclusion: The enteropathogens impaired intestinal-epithelial barrier integrity with dysregulation of claudin-4 and increased bacterial translocation. Enteropathogen-mediated damage was reduced using contra-pathogenicity agents which mitigated the effects of pathogens without direct antimicrobial activity.

Keywords: Citrobacter rodentium; Claudin-4; Cryptosporidium parvum; Enteropathogenic Escherichia coli; Intestinal barrier; Microbial translocation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Translocation / drug effects
  • Bacterial Translocation / physiology*
  • Caco-2 Cells
  • Citrobacter rodentium / drug effects
  • Citrobacter rodentium / metabolism*
  • Cryptosporidium parvum / drug effects
  • Cryptosporidium parvum / metabolism*
  • Enteropathogenic Escherichia coli / drug effects
  • Enteropathogenic Escherichia coli / metabolism*
  • Epidermal Growth Factor / pharmacology
  • Epidermal Growth Factor / therapeutic use
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism*
  • Epithelial Cells / microbiology
  • Humans
  • Hydrocortisone / pharmacology
  • Hydrocortisone / therapeutic use
  • Intestinal Diseases / drug therapy
  • Intestinal Diseases / metabolism
  • Intestinal Diseases / microbiology
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / metabolism*
  • Intestinal Mucosa / microbiology
  • Transendothelial and Transepithelial Migration / drug effects
  • Transendothelial and Transepithelial Migration / physiology

Substances

  • Epidermal Growth Factor
  • Hydrocortisone